Tech Company Financing Transactions
Oncternal Therapeutics Funding Round
Oncternal Therapeutics, based in San Diego, raised $18.4 million from private investors.
Transaction Overview
Company Name
Announced On
2/23/2017
Transaction Type
Venture Equity
Amount
$18,400,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the proceeds to further clinical development programs for cirmtuzumab and TK216, and to advance preclinical development of a new ROR1-targeted antibody-drug conjugate (ADC) program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12230 El Camino Real 300
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Our pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Breitmeyer
Chief Financial Officer
Richard Vincent
Chief Medical Officer
Frank Hsu
Chief Scientific Officer
Gunnar Kaufmann
VP - Bus. Development
Igor Bilinsky
VP - Manufacturing
Rajesh Krishnan
Browse more venture capital transactions:
Prev: 2/23/2017: Bowery Farming venture capital transaction
Next: 2/23/2017: PMV Pharmaceuticals venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs